LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR‐193a/MCL1 pathway

Yilan Wu

doi:10.1002/jbt.22008

journal article Dec 04, 2017

LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR‐193a/MCL1 pathway

Yilan Wu

Journal of Biochemical and Molecular Toxicology Vol. 32 No. 1 · Wiley

View at Publisher Save 10.1002/jbt.22008

Abstract

AbstractAlthough dexamethasone (DEX) remains a first‐line agent for multiple myeloma (MM) therapy, the development of DEX resistance has become an indicator of poor prognosis in MM patients. It is thus urgent to develop strategies to restore the vulnerability of MM to DEX. This study demonstrated long non‐coding RNA (lncRNA) nuclear paraspeckle assembly transcript 1 (NEAT1) was highly expressed in DEX‐resistant myeloma cell lines, and upregulation of NEAT1 was tightly linked to poor prognosis. The in‐depth study revealed that during the development of DEX resistance in these cells, the miR‐193a levels were decreased, which resulted in the increased expression of the target gene myeloid cell leukemia‐1 (MCL1). We also found knockdown of NEAT1, the DEX‐induced sensitivity was enhanced in the resistant cells. Meanwhile, overexpression of NEAT1 increased the DEX‐induced resistance in the sensitive cells. In conclusion, the NEAT1/miR‐193a/MCL1 pathway is closely associated with the development of DEX resistance in myeloma cells, and knockdown of NEAT1 can significantly improve DEX sensitivity in MM.

Topics

No keywords indexed for this article. Browse by subject →

References

27

[1]

Multiple Myeloma

Antonio Palumbo, KENNETH ANDERSON

New England Journal of Medicine 10.1056/nejmra1011442

[2]

10.3109/10428194.2010.528095

[3]

Murray M. Cell Cycle (2014) 10.4161/cc.25251

[4]

10.1007/s12325-016-0413-7

[5]

10.1016/j.canlet.2015.11.024

[6]

Long non-coding RNAs: insights into functions

Tim R. Mercer, Marcel E. Dinger, John S. Mattick

Nature Reviews Genetics 10.1038/nrg2521

[7]

10.3390/ijms16011395

[8]

10.18632/oncotarget.17439

[9]

10.18632/oncotarget.17757

[10]

Chen Z. J. Eur. Rev. Med. Pharmacol. Sci. (2016)

[11]

SUN S.‐J. Eur. Rev. Med. Pharmacol. Sci. (2017)

[12]

M Z. Eur. Rev. Med. Pharmacol. Sci. (2017)

[13]

10.1016/j.ijbiomac.2017.07.053

[14]

Yu X. Cell Prolif. (2017)

[15]

10.3748/wjg.v20.i34.12241

[16]

Human RISC Couples MicroRNA Biogenesis and Posttranscriptional Gene Silencing

Richard I. Gregory, Thimmaiah P. Chendrimada, Neil Cooch et al.

Cell 10.1016/j.cell.2005.10.022

[17]

10.1016/j.canlet.2013.06.013

[18]

10.1038/modpathol.2012.160

[19]

Amagai Y. J. Vet. Med. Sci. (2013) 10.1292/jvms.13-0025

[20]

10.1038/embor.2013.20

[21]

10.1186/s13046-016-0450-8

[22]

10.18632/oncotarget.14332

[23]

Teh T. C. Leukemia (2017)

[24]

10.1182/blood-2016-03-704908

[25]

10.1111/ejh.12901

[26]

10.1186/1476-4598-13-234

[27]

10.3892/ol.2016.5229

Metrics

54

Citations

27

References

Details

Published: Dec 04, 2017
Vol/Issue: 32(1)
License: View

Authors

Y

Yilan Wu

School of Nursing Fujian University of Traditional Chinese Medicine Fujian 350122 People's Republic of China

Funding

Natural Science Foundation of Fujian Province Award: Grant No. 2017J01831

Cite This Article

Yilan Wu (2017). LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR‐193a/MCL1 pathway. Journal of Biochemical and Molecular Toxicology, 32(1). https://doi.org/10.1002/jbt.22008

LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR‐193a/MCL1 pathway

You May Also Like